Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer.
Kubo T, Ichihara E, Harada D, Inoue K, Fujiwara K, Hosokawa S, Kishino D, Kawai H, Ochi N, Oda N, Hara N, Hotta K, Tabata M, Maeda Y, Kiura K.
Kubo T, et al.
Respir Investig. 2023 Sep;61(5):643-650. doi: 10.1016/j.resinv.2023.06.005. Epub 2023 Jul 20.
Respir Investig. 2023.
PMID: 37480603
BACKGROUND: Limited information on anticancer therapy for super-elderly patients with non-small-cell lung cancer is available. Immune checkpoint inhibitors offer long-term survival to elderly patients aged 65 years with non-small-cell lung cancer. ...
BACKGROUND: Limited information on anticancer therapy for super-elderly patients with non-small-cell lung cancer is available. Immune checkp …